hcb1

AZD1940 (UNII-0J0035E9FT)是一种高亲和力的大麻素CB(1) CB(2)受体激动剂，具有口服活性，应用于口面疼痛的研究。

PSNCBAM-1 (PSNCBAM 1) 是一种 CB1 受体负变构调节剂 (EC50 = 0.1 μM)，在体内具有吞噬作用。 PSNCBAM-1 可用于肥胖研究。

Rimonabant (SR141716) 是一种选择性的、能透过血脑屏障的中心大麻素受体 1 拮抗剂， Ki 值为 1.8 nM。它也能够抑制分枝杆菌膜蛋白 3。

Otenabant hydrochloride (Otenabant) 是一种CB1受体高亲和性拮抗剂，Ki=0.7 nM。

KH-CB19 is an effective and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1 CLK4).

Drinabant (AVE-1625) 是具有口服活性的 CB1 受体的拮抗剂。Drinabant 抑制 hCB1-R 和 rCB1-R 激动剂刺激的钙信号的 IC50 分别为 25 nM 和 10 nM。对 hCB2-R 无活性。

RTICBM-189 是可透过血脑屏障的大麻素 1 型受体变构调节剂，在 Ca2+动员试验中pIC50为 7.54，对 hCB1和 mCB1的 pIC50分别为 5.29 和 6.25。

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB1) and the S-(-) enantiomer of the CB1 modulator GAT211. It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB1 full agonist CP 55,940 to CHO cells expressing human recombinant CB1 (hCB1), as well as the activity of 2-arachidonoyl glycerol , arachidonoyl ethanolamide , and CP 55,940 in arrestin2 recruitment assays and increases ERK1 2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB1. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons. GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.

CB1 2 agonist 3 是一种具有竞争性和高效性的 CB1 CB2 激动剂，对 hCB1 和 hCB2 具有很高的亲和力，可用于研究神经系统疾病。

AM8936 is a well-balanced and highly potent agonist for the cannabinoid receptor type-1 (CB1) in functional assays, with EC50 values of 8.6 nM and 1.4 nM for the rat CB1 (rCB1) and human CB1 (hCB1) receptors, respectively. It demonstrates a strong affinity for the rat CB1 receptor, exhibiting a K i value of 0.55 nM. In vivo studies have confirmed that AM8936 is a powerful and effective agonist for the CB1 receptor. Due to its therapeutic potential, AM8936 is particularly valuable for research focused on central nervous system disorders, metabolic disorders, pain management, glaucoma, and other related areas [1].

CB-25是一种CB1大麻素受体的部分激动剂配体。它能增强Forskolin诱导的癌细胞中cAMP的形成，但在Forskolin诱导的hCB1-CHO细胞中则不显示增强作用。